Tong Lin, Huang Shumin, Zheng Chen, Zhang Yuanyuan, Chen Zhimin
Department of Pulmonology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China.
National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou 310052, China.
J Clin Med. 2022 May 17;11(10):2824. doi: 10.3390/jcm11102824.
Refractory pneumonia (RMPP) is a severe state of infection that has attracted increasing universal attention in recent years. The pathogenesis of RMPP remains unknown, but the excessive host immune responses as well as macrolide resistance of M. pneumoniae might play important roles in the development of RMPP. To improve the prognosis of RMPP, it is mandatory to recognize RMPP in the early stages, and the detection of macrolide-resistant MP, clinical unresponsiveness to macrolides and elevated proinflammatory cytokines might be clues. Timely and effective anti-mycoplasmal therapy and immunomodulating therapy are the main strategies for RMPP.
难治性肺炎支原体肺炎（RMPP）是一种严重的感染状态，近年来已引起越来越广泛的普遍关注。RMPP的发病机制尚不清楚，但宿主的过度免疫反应以及肺炎支原体对大环内酯类药物的耐药性可能在RMPP的发展中起重要作用。为改善RMPP的预后，必须在早期识别RMPP，检测大环内酯类耐药的肺炎支原体、对大环内酯类药物的临床无反应性以及促炎细胞因子升高可能是线索。及时有效的抗支原体治疗和免疫调节治疗是RMPP的主要治疗策略。
